Watch highlights from the 2024 conference
Is R&D investment a driver of future growth or merely a requirement to remain competitive?
Will increased emphasis on product safety, efficacy and quality control limit future R&D spend?
Are strategic collaborations, deals, and partnerships the only way to fund future innovation?
These are just some of the questions discussed during our inaugural Animal Health Conference that brought together leading industry experts.
Our guest speakers
David Hallas
CEO, ECO Animal Health plc
David Hallas
CEO, ECO Animal Health plc
David Hallas has been CEO of ECO Animal Health since 2022 and has over three decades of experience in the animal health industry.
David was previously Managing Director of Sure Petcare, a wholly owned subsidiary of Merck Inc., providing digital based solutions to the companion animal sector and Associate Vice President of MSD Animal Health, with a full P&L responsibility of 7 European countries (combined revenue of over $450 million).
Prior to this, David held senior management roles in other animal health businesses within Merck, Schering Plough, and Pfizer (now Zoetis).
David has substantial experience managing profitable growth through the introduction of new products, including vaccines, managing complex R&D projects, and successful M&A integrations.
Laurent Flaus
Co-Founder and CEO, Axience Group
Laurent Flaus
Co-Founder and CEO, Axience Group
Laurent Flaus is the CEO of Axience Group which he co-founded in France in 2001.
Laurent is a qualified vet and holds an MBA from Essec business school.
He started his career at Upjohn (now part of Zoetis) and then became product manager at Hoechst Roussel Vet prior to co-founding Axience.
Since then, Laurent has been leading and growing Axience Group which develops and markets pharmaceutical and OTC products primarily for companion animals. Additionally, he is a member of the board of SIMV, the French association for animal health industry representing manufacturers and marketers of medicines and reagents for pets and livestock.
Simon Middleton
Partner, L.E.K. Consulting
Simon Middleton
Partner, L.E.K. Consulting
Simon Middleton is a Partner in L.E.K.’s London office, and head of the European Life Sciences practice.
Much of his work to date has been for clients in the Pharmaceutical, Biotech, Medtech and Healthcare sectors, as well as for investors in these industries.
David Hallas
CEO, ECO Animal Health plc
David Hallas
CEO, ECO Animal Health plc
David Hallas has been CEO of ECO Animal Health since 2022 and has over three decades of experience in the animal health industry.
David was previously Managing Director of Sure Petcare, a wholly owned subsidiary of Merck Inc., providing digital based solutions to the companion animal sector and Associate Vice President of MSD Animal Health, with a full P&L responsibility of 7 European countries (combined revenue of over $450 million).
Prior to this, David held senior management roles in other animal health businesses within Merck, Schering Plough, and Pfizer (now Zoetis).
David has substantial experience managing profitable growth through the introduction of new products, including vaccines, managing complex R&D projects, and successful M&A integrations.
Laurent Flaus
Co-Founder and CEO, Axience Group
Laurent Flaus
Co-Founder and CEO, Axience Group
Laurent Flaus is the CEO of Axience Group which he co-founded in France in 2001.
Laurent is a qualified vet and holds an MBA from Essec business school.
He started his career at Upjohn (now part of Zoetis) and then became product manager at Hoechst Roussel Vet prior to co-founding Axience.
Since then, Laurent has been leading and growing Axience Group which develops and markets pharmaceutical and OTC products primarily for companion animals. Additionally, he is a member of the board of SIMV, the French association for animal health industry representing manufacturers and marketers of medicines and reagents for pets and livestock.
Simon Middleton
Partner, L.E.K. Consulting
Simon Middleton
Partner, L.E.K. Consulting
Simon Middleton is a Partner in L.E.K.’s London office, and head of the European Life Sciences practice.
Much of his work to date has been for clients in the Pharmaceutical, Biotech, Medtech and Healthcare sectors, as well as for investors in these industries.
Advisory services for private equity
Our team of experienced professionals bring a fresh perspective to any transaction, providing advice, ideas and judgement based on decades of sector knowledge.
Private equity fund finance
Our creative financing solutions provide funds with the support and flexibility to seize opportunities, deliver returns and generate value. Our services include capital call facilities, secondary fund leverage, NAV financing and GP financing.